Company: AZN
Filing Date: 2025-12-01
Form Type: 6-K
Source: 0001654954-25-013569
Chunk: 1

Company: ASTRAZENECA PLC
Filing Date: 2025-12-01
Form: 6-K
Chunk 1
---
 | To: | 30 NOVEMBER 2025 |
| Balance of unallotted securities under scheme(s) from previous   
 return:                                                          |       |                                                         3,688,383 |     |                  |
| Plus:The                                                         
 amount by which the block scheme(s) has been increased since the 
 date of the last return (if any increase has been applied        
 for):                                                            |       |                                                                 0 |     |                  |
| Less:Number                                                      
 ofsecuritiesissued/allotted                                      
 under scheme(s) during period (see UKLR                          
 20.6.7G):                                                        |       |                                                            67,907 |     |                  |
| Equals:Balance                                                   
 under scheme(s) not yet issued/allotted at end of                
 period:                                                          |       |                                                         3,620,476 |     |                  |

| Name of contact:             | Hannah Tattersall   |
| Telephone number of contact: | +44 (0)20 3749 5000 |

#### AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

#### Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date:01 December 2025

| By: /s/           
 Matthew Bowden    |
| Name:             
 Matthew Bowden    |
| Title:            
 Company Secretary |